• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness
In conclusion, all modeled two-dose UVV strategies were projected to substantially reduce the clinical and economic burden of varicella disease in Denmark compared to the current no vaccination strategy, with declines in both varicella and zoster incidence for all age groups over a 50-year time horizon.PMID:37018165 | DOI:10.1371/journal.pgph.0001743
Source: Herpes - April 5, 2023 Category: Infectious Diseases Authors: Colleen Burgess Salome Samant Thomas leFevre Carsten Schade Larsen Manjiri Pawaskar Source Type: research

Incident Herpes Zoster and Risk of Dementia: A Population-Based Danish Cohort Study
DISCUSSION: Herpes zoster is not associated with increased risk of dementia, and contrary to expectation we found a small decrease in risk. The explanation for this finding is unclear, and systematic errors should be considered. Patients with central nervous system involvement had almost two-fold increased relative risk of dementia. The population attributable fraction of dementia due to this rare complication is estimated at 0.014%. Therefore, universal vaccination against varicella-zoster virus in the elderly is unlikely to reduce dementia risk.PMID:35676090 | DOI:10.1212/WNL.0000000000200709
Source: Herpes - June 8, 2022 Category: Infectious Diseases Authors: Sigrun Alba Johannesdottir Schmidt Katalin Veres Henrik Toft S ørensen Niels Obel Victor W Henderson Source Type: research

Vaccination against herpes zoster
Ugeskr Laeger. 2021 Nov 22;183(47):V07210585.ABSTRACTDuring their lifetime, 25% of Danes will experience an episode of herpes zoster (HZ). In 15-20% of these 25% HZ will be complicated by postherpetic neuralgia (PHN). The European Medicines Agency has approved two vaccines against HZ, a live attenuated vaccine (ZLV) and a recombinant adjuvanted vaccine (RZV). The efficacy of ZLV against HZ is moderate (51%), age-dependent and declines in 5-8 years. RZV has shown greater-than 90% protection against HZ and PHN across age groups for ≥ 9 years as summarised in this review. Vaccination of everybody > 50 years of age and im...
Source: Herpes - December 1, 2021 Category: Infectious Diseases Authors: Carsten Schade Larsen Marie Helleberg Source Type: research

Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019
ConclusionThe immunity gaps found primarily in young HCW indicate a need for a screening and vaccination strategy for this group. Considering the poor correlation between self-reported immunity and seropositivity, efforts should be made to check HCW's immune status in order to identify those who would benefit from vaccination.PMID:33928900 | PMC:PMC8086246 | DOI:10.2807/1560-7917.ES.2021.26.17.2001167
Source: Euro Surveill - April 30, 2021 Category: Infectious Diseases Authors: Marie-Louise von Linstow Alex Yde Nielsen Nikolai Kirkby Anna Eltvedt Thilde Nordmann Winther Allan Bybeck Nielsen Didi Bang Anja Poulsen Source Type: research